Table: q1_q4_2022_prescription_drug_wac_increases , manufacturer_name like H*

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  *

oshpd_id	manufacturer_name	date_reported	ndc_number	drug_product_description	wac_effective_date	wac_increase_amount	wac_after_increase	patent_expiration_date	drug_source_type	unit_sales_volume_in_us	unit_sales_volume_non_public_indicator	cost_increase_factors	cost_increase_factors_non_public_indicator	change_improvement_description	change_improvement_non_public_indicator	acquisition_date	company_acquired_from	acquisition_price	acquisition_price_non_public_indicator	acquisition_price_comment	wac_at_acquisition	wac_year_prior_to_acquisition	year_drug_introduced_to_market	wac_at_intro_to_market	supporting_documents	general_comments
Rx0000298	H2-Pharma LLC	12/31/2022	61269041020	Etopophos (etoposide phosphate), powder, 100 mg, single-dose vial	10/31/2022	15.35	170.35	None	Single Source Drug	18000	None	Inflation	None	Price on cold packs increased	None	03/01/2020	Bristol-Meyers Squibb	None	1	None	140.94	140.94	1996	99.31	None	None
Rx0000164	Harmony Biosciences, LLC	03/31/2022	72028017803	Wakix Oral Tablet 17.8 MG, 30 each	01/03/2022	324.05	6804.95	09/26/2029	Single Source Drug	None	1	The pricing decisions are determined after careful consideration of many interdependent factors including but not limited to clinical and economic value of the particular therapy, therapeutic category, overall market dynamics, competitor pricing, discounts provided to customers, and overall research and development costs	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000164	Harmony Biosciences, LLC	03/31/2022	72028004503	Wakix Oral Tablet 4.45 MG, 30 each	01/03/2022	162.02	3402.47	09/26/2029	Single Source Drug	None	1	The pricing decisions are determined after careful consideration of many interdependent factors including but not limited to clinical and economic value of the particular therapy, therapeutic category, overall market dynamics, competitor pricing, discounts provided to customers, and overall research and development costs	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000144	Helsinn Therapeutics, Inc	09/30/2022	69639012001	VALCHLOR 0.016% Gel 60mg Tube	07/01/2022	341.23	5215.92	07/08/2029	Single Source Drug	4229	None	The increase in WAC is based on business factors, including the cost of funding assistance programs for eligible patients and clinical research, including research relating to potential new indications.	None	None	1	None	None	None	None	None	None	None	None	None	None	None
Rx0000178	Hikma Pharmaceuticals USA Inc	06/30/2022	00143978710	Enalaprilat Injection 1.25mg/mL, 10 vials	06/01/2022	4.78	53.09	None	Non-innovator Multiple Source Drug	None	1	Increases in rate of inflation and ongoing changes in competitive market analysis, market conditions and dynamics.	None	None	1	None	None	None	None	None	None	None	None	None	None	Pursuant to CA Health & Safety Code §127679, Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma did not acquire this product.
Rx0000178	Hikma Pharmaceuticals USA Inc	06/30/2022	00143978610	Enalaprilat Injection 2.5mg/2mL, 10 vials	06/01/2022	8.54	94.82	None	Non-innovator Multiple Source Drug	None	1	Increases in rate of inflation and ongoing changes in competitive market analysis, market conditions and dynamics.	None	None	1	None	None	None	None	None	None	None	None	None	None	Pursuant to CA Health & Safety Code §127679, Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma did not acquire this product.
Rx0000178	Hikma Pharmaceuticals USA Inc	09/30/2022	00641047721	PHENobarbital Sodium Injection Solution 130 MG/ML, 1 vial	07/05/2022	6.16	68.40	None	Non-innovator Multiple Source Drug	None	1	Increased shipping and distribution costs.	None	None	1	None	None	None	None	None	None	None	None	None	None	Pursuant to CA Health & Safety Code §127679, Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma did not acquire this product.
Rx0000178	Hikma Pharmaceuticals USA Inc	09/30/2022	00641047725	PHENobarbital Sodium Injection Solution 130 MG/ML, 25 vials	07/05/2022	154.04	1709.95	None	Non-innovator Multiple Source Drug	None	1	Increased shipping and distribution costs.	None	None	1	None	None	None	None	None	None	None	None	None	None	Pursuant to CA Health & Safety Code §127679, Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma did not acquire this product.
Rx0000178	Hikma Pharmaceuticals USA Inc	09/30/2022	00641047625	PHENobarbital Sodium Injection Solution 65 MG/ML	07/05/2022	59.35	658.85	None	Non-innovator Multiple Source Drug	None	1	Increased shipping and distribution costs.	None	None	1	None	None	None	None	None	None	None	None	None	None	Pursuant to CA Health & Safety Code §127679, Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma did not acquire this product.
Rx0000178	Hikma Pharmaceuticals USA Inc	09/30/2022	00641620825	Promethazine HCl Injection Solution 25 MG/ML	07/01/2022	19.98	43.64	None	Non-innovator Multiple Source Drug	None	1	Increases in rate of inflation and ongoing changes in competitive market analysis, market conditions and dynamics.	None	None	1	None	None	None	None	None	None	None	None	None	None	Pursuant to CA Health & Safety Code §127679, Hikma is limiting its response to that which is otherwise in the public domain or publicly available. Hikma did not acquire this product.
Rx0000145	Horizon Therapeutics USA, Inc.	09/30/2022	75987008010	Product Name: KRYSTEXXA; Drug product strength: 1 mL sterile concentrate for dilution containing 8 mg of pegloticase protein, expressed in uricase protein amounts. Drug product dosage form: vial. Drug product package size: 8 MG/ML single use vial	07/29/2022	624.97	26665.22	None	Single Source Drug	None	1	None	1	None	1	None	None	None	None	None	None	None	None	None	None	Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Horizon believes is otherwise in the public domain or publicly available. Please note the Patent Expiration date for Krystexxa is not publicly available.